{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:12:15Z","timestamp":1780481535031,"version":"3.54.1"},"reference-count":69,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2011,11,23]]},"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>The publication of the BEAT-ROP study of bevacizumab (Avastin) treatment for Zone I and II retinopathy of prematurity (ROP) has raised hopes that there might now be a simpler, cheaper and more effective treatment than laser therapy, the current standard of care. However, we would urge caution at this point in time. We review the scientific background to the use of intravitreal anti-vascular endothelial growth factor for ROP, highlight a number of design issues in the BEAT-ROP study and problems with interpretation of the results. For example, no visual outcomes were reported and the study was underpowered to assess longer term safety. Intravitreal bevacizumab leaks into the systemic circulation in animals and adult humans and there are real concerns of potential harm to the developing preterm infant because vascular growth factors play a critical role in organogenesis. We conclude that bevacizumab should be reserved for exceptional circumstances and compassionate use pending further studies. Laser remains the proven effective therapy for first line treatment of all forms of ROP with little systemic morbidity. Neonatology and ophthalmology have an impressive record of conducting collaborative multicentre studies and we urgently need further rigorously designed, adequately powered randomised trials of anti-VEGF agents that evaluate visual outcomes as well as short and long term ocular and systemic safety.<\/jats:p>","DOI":"10.1136\/archdischild-2011-301148","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T21:43:16Z","timestamp":1325281396000},"page":"F170-F174","source":"Crossref","is-referenced-by-count":90,"title":["Are we there yet? Bevacizumab therapy for retinopathy of prematurity"],"prefix":"10.1136","volume":"98","clinical-trial-number":[{"clinical-trial-number":"nct01096784","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Brian A","family":"Darlow","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L","family":"Ells","sequence":"additional","affiliation":[{"name":"Calgary Retina Consultants, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare E","family":"Gilbert","sequence":"additional","affiliation":[{"name":"International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen A","family":"Gole","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics and Child Health, University of Queensland, Royal Children's Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham E","family":"Quinn","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,12,30]]},"reference":[{"key":"2025090511411347000_98.2.F170.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025090511411347000_98.2.F170.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1100248"},{"key":"2025090511411347000_98.2.F170.3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"key":"2025090511411347000_98.2.F170.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1103460"},{"key":"2025090511411347000_98.2.F170.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2011.02330.x"},{"key":"2025090511411347000_98.2.F170.6","first-page":"137","article-title":"The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases","volume":"68","author":"Michaelson","year":"1948","journal-title":"Trans Ophthalmol Soc UK"},{"key":"2025090511411347000_98.2.F170.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.38.7.397"},{"key":"2025090511411347000_98.2.F170.8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"2025090511411347000_98.2.F170.9","unstructured":"Palmer EA Biglan AW Hardy RJ . Retinal ablative therapy for active proliferative retinopathy of prematurity: history, current status and prospects. In: Contemporary Issues in F et al Neonatal Medicine: Retinopathy of Prematurity. Silverman WA Flynn JT , eds. Boston: Publ Blackwell Scientific 1985."},{"key":"2025090511411347000_98.2.F170.10","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1988.01060130517027"},{"key":"2025090511411347000_98.2.F170.11","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.3.311"},{"key":"2025090511411347000_98.2.F170.12","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald Lecture","volume":"19","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090511411347000_98.2.F170.13","doi-asserted-by":"publisher","DOI":"10.1542\/neo.10-11-e550"},{"key":"2025090511411347000_98.2.F170.14","first-page":"96","article-title":"Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American ophthalmological society thesis)","volume":"108","author":"Hartnett","year":"2010","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2025090511411347000_98.2.F170.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm0195-27"},{"key":"2025090511411347000_98.2.F170.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.06.014"},{"key":"2025090511411347000_98.2.F170.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10457"},{"key":"2025090511411347000_98.2.F170.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.12.1509"},{"key":"2025090511411347000_98.2.F170.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025090511411347000_98.2.F170.20","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.099598"},{"key":"2025090511411347000_98.2.F170.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2025090511411347000_98.2.F170.22","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.12.1684"},{"key":"2025090511411347000_98.2.F170.23","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"2025090511411347000_98.2.F170.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.10.007"},{"key":"2025090511411347000_98.2.F170.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.05.031"},{"key":"2025090511411347000_98.2.F170.26","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2008.1"},{"key":"2025090511411347000_98.2.F170.27","doi-asserted-by":"publisher","DOI":"10.1080\/08820530701420082"},{"key":"2025090511411347000_98.2.F170.28","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.145"},{"key":"2025090511411347000_98.2.F170.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2010.05.011"},{"key":"2025090511411347000_98.2.F170.30","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.141481"},{"key":"2025090511411347000_98.2.F170.31","doi-asserted-by":"crossref","unstructured":"Harder BC Baltz SV Jonas JB . Intravitreal Bevacizumab for Retinopathy of Prematurity. J Ocul Pharmacol Ther 2011;(In Press).","DOI":"10.1001\/archophthalmol.2012.1"},{"key":"2025090511411347000_98.2.F170.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.007"},{"key":"2025090511411347000_98.2.F170.33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702683"},{"key":"2025090511411347000_98.2.F170.34","unstructured":"FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections. http:\/\/www.fda.gov\/Drugs\/Drugsafety\/ucm270296.htm (accessed 26 September 2011)."},{"key":"2025090511411347000_98.2.F170.35","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3928\/01913913-20101217-06","article-title":"Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity","volume":"47 Online","author":"Suk","year":"2010","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025090511411347000_98.2.F170.36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"key":"2025090511411347000_98.2.F170.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2009.12.002"},{"key":"2025090511411347000_98.2.F170.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.51"},{"key":"2025090511411347000_98.2.F170.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109550"},{"key":"2025090511411347000_98.2.F170.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.040"},{"key":"2025090511411347000_98.2.F170.41","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1171"},{"key":"2025090511411347000_98.2.F170.42","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4140"},{"key":"2025090511411347000_98.2.F170.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.09.012"},{"key":"2025090511411347000_98.2.F170.44","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4425"},{"key":"2025090511411347000_98.2.F170.45","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"2025090511411347000_98.2.F170.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2009.03.006"},{"key":"2025090511411347000_98.2.F170.47","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.156810"},{"key":"2025090511411347000_98.2.F170.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.021"},{"key":"2025090511411347000_98.2.F170.49","unstructured":"Sato T Wada K Arahori H . Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2011;(In Press)."},{"key":"2025090511411347000_98.2.F170.50","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"Gerber","year":"1999","journal-title":"Development"},{"key":"2025090511411347000_98.2.F170.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.01.022"},{"key":"2025090511411347000_98.2.F170.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdevneu.2011.04.004"},{"key":"2025090511411347000_98.2.F170.53","doi-asserted-by":"publisher","DOI":"10.2307\/3454543"},{"key":"2025090511411347000_98.2.F170.54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200611-1660PP"},{"key":"2025090511411347000_98.2.F170.55","doi-asserted-by":"publisher","DOI":"10.1038\/nm1102-1329b"},{"key":"2025090511411347000_98.2.F170.56","doi-asserted-by":"crossref","first-page":"L555","DOI":"10.1152\/ajplung.00408.2001","article-title":"Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure","volume":"283","author":"Le Cras","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025090511411347000_98.2.F170.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.08.003"},{"key":"2025090511411347000_98.2.F170.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01107-0"},{"key":"2025090511411347000_98.2.F170.59","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1180"},{"key":"2025090511411347000_98.2.F170.60","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181a68f3a"},{"key":"2025090511411347000_98.2.F170.61","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90208-2"},{"key":"2025090511411347000_98.2.F170.62","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90223-6"},{"key":"2025090511411347000_98.2.F170.63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7210873"},{"key":"2025090511411347000_98.2.F170.64","doi-asserted-by":"publisher","DOI":"10.1203\/01.PDR.0000151693.46655.66"},{"key":"2025090511411347000_98.2.F170.65","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92557-V"},{"key":"2025090511411347000_98.2.F170.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100441"},{"key":"2025090511411347000_98.2.F170.67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-11-6","article-title":"NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol","volume":"11","author":"Askie","year":"2011","journal-title":"BMC Pediatr"},{"key":"2025090511411347000_98.2.F170.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.07.013"},{"key":"2025090511411347000_98.2.F170.69","unstructured":"Report of the Australian and New Zealand Neonatal Network (ANZNN) 2006. http:\/\/www.npsu.unsw.edu.au\/PRERUWeb.nsf\/page\/ANZNN+reports (accessed 16 September 2011)."}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2011-301148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:58:43Z","timestamp":1757098723000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2011-301148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,30]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,15]]},"published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1136\/archdischild-2011-301148"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2011-301148","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,30]]}}}